Therapeutic targeting of hepatic ACSL4 ameliorates NASH in mice.

Therapeutic targeting of hepatic ACSL4 ameliorates NASH in mice.
复制标题

DOI:
10.1002/hep.32148
复制
发表时间:
2022-01
期刊:
Hepatology (Baltimore, Md.)
影响因子:
--
通讯作者:
Yang Y
Yang Y
中科院分区:
其他
文献类型:
--
作者:
Duan J;Wang Z;Duan R;Yang C;Zhao R;Feng Q;Qin Y;Jiang J;Gu S;Lv K;Zhang L;He B;Birnbaumer L;Yang S;Chen Z;Yang Y

文献摘要

参考文献

被引文献

相似文献

在全球范围内,NAFLD是最常见的肝脏疾病之一,估计男性患病率超过30%,女性患病率超过15%,2型糖尿病患者的患病率甚至更高。NAFLD的最佳药物治疗方法是迫切需要的。在这项研究中,我们发现与健康对照组相比,NAFLD患者的肝脏ACSL 4水平升高。抑制ACSL 4表达可促进线粒体呼吸,从而增强肝细胞介导脂肪酸β-氧化的能力,并通过上调PGC 1 α使脂质蓄积最小化。此外,我们发现abemaciclib是一种有效的选择性ACSL 4抑制剂,低剂量abemaciclib可显著改善多种NAFLD小鼠模型的大多数NAFLD症状。因此,抑制ACSL 4是NAFLD的潜在替代治疗方法。
Globally, NAFLD is one of the most common liver disorders, with an estimated prevalence rate of more than 30% in men and 15% in women, and an even higher prevalence in people with type 2 diabetes mellitus. Optimal pharmacologic therapeutic approaches for NAFLD are an urgent necessity. In this study, we showed that compared to healthy controls, hepatic ACSL4 levels in NAFLD patients were found to be elevated. Suppression of ACSL4 expression promoted mitochondrial respiration, thereby enhancing the capacity of hepatocytes to mediate β-oxidation of fatty acids and to minimize lipid accumulation by up-regulating PGC1α. Moreover, we found that abemaciclib is a potent and selective ACSL4 inhibitor, low-dose of abemaciclib significantly ameliorated most of the NAFLD symptoms in multiple NAFLD mice models. Therefore, inhibition of ACSL4 is a potential alternative therapeutic approach for NAFLD.
DOI: 10.1158/1078-0432.ccr-18-1256
发表时间: 2018-12-01
期刊: Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子: --
作者:
Dowless M;Lowery CD;Shackleford T;Renschler M;Stephens J;Flack R;Blosser W;Gupta S;Stewart J;Webster Y;Dempsey J;VanWye AB;Ebert P;Iversen P;Olsen JB;Gong X;Buchanan S;Houghton P;Stancato L
通讯作者: Stancato L
ACSL4 通过塑造细胞脂质成分来决定铁死亡敏感性。
DOI: 10.1038/nchembio.2239
发表时间: 2017-01
影响因子: 14.8
作者:
Doll S;Proneth B;Tyurina YY;Panzilius E;Kobayashi S;Ingold I;Irmler M;Beckers J;Aichler M;Walch A;Prokisch H;Trümbach D;Mao G;Qu F;Bayir H;Füllekrug J;Scheel CH;Wurst W;Schick JA;Kagan VE;Angeli JP;Conrad M
通讯作者: Conrad M
DOI: 10.1046/j.1365-2036.2001.01083.x
发表时间: 2001-10-01
影响因子: 7.6
作者:
Hasegawa, T;Yoneda, M;Terano, A
通讯作者: Terano, A
DOI: 10.1074/jbc.m010793200
发表时间: 2001-07-06
影响因子: 4.8
作者:
Kim, JH;Lewin, TM;Coleman, RA
通讯作者: Coleman, RA
DOI: 10.1136/gutjnl-2015-310798
发表时间: 2016-07
期刊: Gut
影响因子: 24.5
作者:
Montagner A;Polizzi A;Fouché E;Ducheix S;Lippi Y;Lasserre F;Barquissau V;Régnier M;Lukowicz C;Benhamed F;Iroz A;Bertrand-Michel J;Al Saati T;Cano P;Mselli-Lakhal L;Mithieux G;Rajas F;Lagarrigue S;Pineau T;Loiseau N;Postic C;Langin D;Wahli W;Guillou H
通讯作者: Guillou H